This trial is testing if a new cancer drug is safe and effective in treating Merkel Cell Carcinoma.
1 Primary · 2 Secondary · Reporting Duration: Up to 3 years
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: Cemiplimab-Rwlc · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: